Movement Alert|Revolution Medicines, Inc. Pre-Market Rise 4.1%, EU Approves Rasonque for Metastatic Pancreatic Cancer

Market Focus
11/20

On November 20, Revolution Medicines, Inc. rose 4.1% in Pre-Market Trading, with the stock trading at $164.0 and turnover of $53.26 thousand.

The clearest catalyst is the company’s recently disclosed European Commission approval of Rasonque monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, with or without an identified RAS tumor mutation.

The authorization covers European Union member states and the European Economic Area, though not the UK or Switzerland. The approval was supported by a phase 3 trial that met all primary and key secondary endpoints, extending the drug’s commercial reach beyond the US. Supporting sentiment has also remained constructive, with RBC earlier raising its price target to $321 and maintaining an Outperform rating after the company’s latest quarterly update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10